“Daily aspirin recommended in US but still not in Britain”

This headline recently appeared in the Telegraph. The article discusses new recommendations about aspirin use from a group of health officials in the United States (US), and how they differ to those in the United Kingdom (UK). The US recommendations suggest that people aged between 50 and 69 who are known to have a moderate increased risk of heart disease should consider taking daily aspirin to reduce the risk of developing bowel cancer as well as heart and circulatory problems.

This is not the current recommendation in the UK, and doesn’t provide a recommendation for those who have had cancer. The best way to find out more about the health benefits of aspirin is in a clinical trial.

The Add-Aspirin trial is testing whether daily aspirin can prevent cancer returning after cancer treatment, and will also test the other potential health benefits of aspirin including the prevention of heart and circulatory problems. It will also assess whether aspirin help prevent new cancers developing.  The results of trials such as Add-Aspirin will help guide health officials on future recommendations about aspirin use.

Contact Details

If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.

For healthcare professionals

Please log into the members area for Add-Aspirin contact details.

Register Interest

For healthcare professionals

If your centre would like to recruit participants to Add-Aspirin, contact us:

Register a participant

From Monday 16th March 2020, to RANDOMISE a participant in the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.

To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.

Unblind a participant in the UK

Unblind a participant in the RoI

Unblind a participant in India